ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

LGVN Longeveron Inc

1.03
-0.02 (-1.90%)
08 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Longeveron Inc NASDAQ:LGVN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -1.90% 1.03 1.03 1.07 1.06 1.02 1.06 158,516 01:00:00

Longeveron to Present at the Planet MicroCap Showcase

25/04/2024 9:05pm

GlobeNewswire Inc.


Longeveron (NASDAQ:LGVN)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Longeveron Charts.

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024.

Details for the Company’s presentation:

 Date:Wednesday, May 1, 2024
 Time:4:30 p.m. PT
 Webcast:Click Here
   

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

If you would like to book 1x1 investor meetings with Longeveron Inc. and to attend the Planet MicroCap Showcase: VEGAS 2024, please register here: https://planetmicrocapshowcase.com/signup.

1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor Contact:

Derek Cole Investor Relations Advisory Solutions derek.cole@iradvisory.com

1 Year Longeveron Chart

1 Year Longeveron Chart

1 Month Longeveron Chart

1 Month Longeveron Chart